SurModics, Inc. (NASDAQ:SRDX) will issue its quarterly earnings data on Wednesday, November 16th. Parties interested in participating in the company’s conference call can do so using this link.

Earnings History for SurModics (NASDAQ:SRDX)

Shares of SurModics, Inc. (NASDAQ:SRDX) opened at 27.90 on Tuesday. The firm has a 50-day moving average price of $27.70 and a 200-day moving average price of $25.95. The firm has a market cap of $363.96 million, a price-to-earnings ratio of 41.70 and a beta of 0.98. SurModics, Inc. has a 12-month low of $17.45 and a 12-month high of $30.75.

A number of analysts have recently commented on the company. Sidoti lowered SurModics from a “buy” rating to a “neutral” rating and set a $33.00 price target on the stock. in a report on Thursday, October 6th. Zacks Investment Research upgraded SurModics from a “hold” rating to a “buy” rating and set a $32.00 price target on the stock in a report on Thursday, October 20th.

In related news, VP Charles W. Olson sold 9,936 shares of the company’s stock in a transaction dated Wednesday, August 17th. The stock was sold at an average price of $28.98, for a total transaction of $287,945.28. Following the sale, the vice president now owns 33,098 shares in the company, valued at $959,180.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Gary R. Maharaj sold 5,000 shares of the company’s stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $25.22, for a total value of $126,100.00. Following the sale, the chief executive officer now owns 130,207 shares in the company, valued at approximately $3,283,820.54. The disclosure for this sale can be found here. Corporate insiders own 7.20% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. raised its stake in SurModics by 5.5% in the third quarter. Ameriprise Financial Inc. now owns 68,933 shares of the company’s stock valued at $2,075,000 after buying an additional 3,585 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its position in shares of SurModics by 0.6% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 416,238 shares of the company’s stock worth $12,525,000 after buying an additional 2,580 shares during the period. TIAA CREF Investment Management LLC increased its position in shares of SurModics by 8.8% in the third quarter. TIAA CREF Investment Management LLC now owns 54,160 shares of the company’s stock worth $1,630,000 after buying an additional 4,373 shares during the period. Teachers Advisors LLC increased its position in shares of SurModics by 37.7% in the third quarter. Teachers Advisors LLC now owns 30,816 shares of the company’s stock worth $927,000 after buying an additional 8,439 shares during the period. Finally, New York State Common Retirement Fund increased its position in shares of SurModics by 28.6% in the third quarter. New York State Common Retirement Fund now owns 15,300 shares of the company’s stock worth $460,000 after buying an additional 3,400 shares during the period. Institutional investors and hedge funds own 87.59% of the company’s stock.

SurModics Company Profile

SurModics, Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company is focused on to transform its medical device business from being a provider of coating technologies to offering whole product solutions to medical device customers.

5 Day Chart for NASDAQ:SRDX

Receive News & Stock Ratings for SurModics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics Inc. and related stocks with our FREE daily email newsletter.